CAH

CARDINAL HEALTH INC

Healthcare | Large Cap

$3.09

EPS Forecast

$64,405

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-07-16

Cardinal Health Q3 FY26: A Non-GAAP Sprint in a GAAP Treadmill, and What It Signals for the Sector

Lead: CAH’s Q3 snapshot—EPS mix, a big impairment, and a clearer path on guidance

Cardinal Health ticker CAH reported its third quarter of fiscal year 2026 with a mixed geometry: revenue of $60.9 billion—an 11% lift year over year—on the top line, while earnings remained a tale of two metrics. GAAP operating earnings slipped, and GAAP diluted EPS came in softer, even as non-GAAP metrics pressed higher. Investors will parse the split: a $184 million pre-tax goodwill impairment tied to Navista & ION weighed on GAAP, but non-GAAP performance captured momentum in the core franchises. The result is a narrative where the headline number moves with the impairment card, while the underlying operating gains fuel a raised outlook via non-GAAP EPS and a reaffirmed, cleaner guidance band.

In practical terms, this is the kind of report where the EPS narrative matters just as much as the revenue line, and where EPS consensus comparisons aren’t baked into the press release the way a quarterly forecast is baked into a bakery. The company’s communications push both GAAP and non-GAAP views, signaling a discipline shift that could shape how investors compare Cardinal Health to its healthcare distribution and services peers going forward.

Numbers at a glance

  • Revenue: $60.9 billion for Q3 FY26, up 11% year over year.
  • GAAP operating earnings: $509 million, down about 30% compared with the prior year quarter.
  • GAAP diluted EPS: $1.69.
  • Non-GAAP operating earnings: $956 million, up 18% year over year.
  • Non-GAAP diluted EPS: $3.17, up 35% year over year.
  • Guidance: Non-GAAP EPS guidance for fiscal year 2026 raised to a range of $10.70 to $10.80.
  • Capital actions: Reduced debt and completed an additional $250 million share repurchase, bringing FY26 repurchase total to about $1.0 billion.

Management emphasizes that the quarter’s GAAP softness is heavily influenced by a one-time impairment—a reminder that GAAP results can be confounded by non-operational items even when the business remains on a growth track.

Impairment impact and the non-GAAP resilience

The press release lays out a $184 million pre-tax goodwill impairment in the Navista & ION reporting unit, tied to changes in risk profiles and a higher discount rate. It’s the kind of charge that makes GAAP numbers move more slowly than the business momentum would suggest. The non-GAAP view, by contrast, shows strength in core operations: non-GAAP operating earnings up 18%, and non-GAAP EPS higher by 35% to $3.17, aided by a lower tax-rate leash and a smaller share count.

Analysts and investors will weigh whether this impairment signals a rebalancing of the portfolio or a drag on long-run value; either way, the non-GAAP narrative lands more favorably, reinforcing the company’s long-term growth ambitions through its Pharmaceutical and Specialty Solutions segments and other growth initiatives.

Guidance and what it implies for the revenue forecast

The updated EPS guidance window — $10.70–$10.80 on a non-GAAP basis — suggests management is confident in continued operating leverage and a favorable tax and share-count environment. The revision tightens the range, which can help reduce earnings volatility and align investor expectations with a more predictable earnings path. Notably, the company also points to debt reduction and a continued plan to deploy capital via share repurchases, signaling an intent to optimize capital structure alongside earnings growth.

From a revenue forecast perspective, the quarter’s result reinforces a narrative of resilient demand in Cardinal Health’s core franchises, even as impairment-related GAAP headwinds remind you that the gamma of accounting constraints can obscure the underlying health of the business. The quantitative setup implies management remains focused on cash flow generation and margin discipline as a pathway to durable earnings expansion across fiscal year 2026.

What this means for Cardinal Health and sector peers

For Cardinal Health, the Q3 results crystallize a nuanced thesis: solid revenue growth and a meaningful non-GAAP earnings ramp sit behind a GAAP tableau darkened by a one-off impairment. The EPS momentum on the non-GAAP line provides credence to the company’s strategy around pharmaceutical distribution and healthcare services, even as investors calibrate the implications of impairment charges on the reported profit base.

Peer-wise, the quarter underscores a broader takeaway for healthcare distributors and diversified services firms: non-GAAP profitability can outpace GAAP at the operating level, particularly when one-off charges or changes in discount rates unsettle the GAAP narrative. In a sector where capital discipline and cost-to-serve efficiency matter for long-run margin resilience, the combination of a higher earnings power signal and a disciplined capital plan (debt reduction, buybacks) can differentiate those that navigate impairment headwinds from those that preempt them with tighter cost management.

Key takeaways for the market

· The CAH quarterly frame reinforces a common motif in large, value-driven healthcare players: the ability to generate top-line growth while GAAP profits swallow one-time charges. Investors will watch whether this division between GAAP and non-GAAP trajectories persists into the rest of FY26.

· The elevation and narrowing of the revenue forecast trajectory, complemented by a robust non-GAAP EPS path, could make CAH an anchor for comparisons with peers that emphasize cash flow quality and earnings power over headline GAAP noise.

· The impaired goodwill charge is a reminder that strategic repositioning or portfolio optimization—while essential—can surface in the GAAP line before the non-GAAP narrative catches up. Sector peers with similar impairment risk should consider how to communicate the offsetting operating gains that investors care about in the near term.

Bottom line

Cardinal Health’s third quarter paints a portrait of a company executing within its growth platforms while wrestling with accounting headwinds that are not about the core market demand. The non-GAAP strength offers a case for optimistic re-rating if the earnings cadence remains steady, even as the GAAP picture remains a ledger of one-off adjustments. For the sector, the message is that discipline around cost, capital allocation, and a clear revenue forecast can sustain multiple expansion in a market where investors have learned to look past one-off impairments to the underlying engine of cash generation.